Top Baricitinib (1187594-09-7)&Baricitinib Phosphate (1187595-84-1) GMP Manufacture and intermediates

GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.

Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.

www.eosmedchem.com

1.

Baricitinib, CAS#: 1187594-09-7 (free base), HPLC 99.62%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.

Name: Baricitinib 

CAS#: 1187594-09-7 (free base) 

Chemical Formula: C16H17N7O2S 

Exact Mass: 371.11644 

Molecular Weight: 371.41688 

Elemental Analysis: C, 51.74; H, 4.61; N, 26.40; O, 8.62; S, 8.63

Baricitinib Phosphate , CAS#: 1187595-84-1 (free base), HPLC 99.5%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.

Name: Baricitinib Phosphate 

CAS#: 1187595-84-1 (phosphate) 

Chemical Formula: C16H20N7O6PS 

Exact Mass: 

Molecular Weight: 469.4128 

Elemental Analysis: C, 40.94; H, 4.29; N, 20.89; O, 20.45; P, 6.60; S, 6.83

2.

Baricitinib intermediates:

Baricitinib intermediate, 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile, CAS# 1187595-85-2, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate, CAS# 1153949-11-1, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, 1-Boc-3-azetidinone, CAS# 398489-26-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl-7H-pyrrolo[2,3-d]pyrimidine, CAS# 941685-27-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate,1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, CAS# 1029716-44-6, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate,4-Chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine, CAS# 941685-26-3, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, 4-Chloropyrrolo[2,3-d]pyrimidine, CAS# 3680-69-1, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, 2-(azetidin-3-ylidene)acetonitrile (hydrochloride), CAS# 1314910-43-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

Baricitinib intermediate, 4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine, CAS# 1187595-88-5, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.

ADDITIONAL INFORMATION

Related CAS# 

1187594-09-7 (Baricitinib free base) 

1187595-84-1 (Baricitinib phosphate)

REFERENCES

1: Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015 Apr. PubMed PMID: 26137574; PubMed Central PMCID: PMC4486197.

2: Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, Wang X, Shi ZZ, Lewis DE, Wu H, Ballantyne CM. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015 Jun 4. doi: 10.1038/ijo.2015.104. [Epub ahead of print] PubMed PMID: 26041698.

3: Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27. PubMed PMID: 25431052; PubMed Central PMCID: PMC4316868.

4: Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014 Dec;54(12):1354-61. doi: 10.1002/jcph.354. PubMed PMID: 24965573.

5: Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12. Review. PubMed PMID: 24818516.

6: Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26. PubMed PMID: 24072562.

7: van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol. 2013 May;25(3):391-7. doi: 10.1097/BOR.0b013e32835fd828. Review. PubMed PMID: 23492738.

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

2018. 4.18 Janpan CPHI, Attend

2018. 5.15 Israel Biomed, Attend

2018. 6. 20 China CPHI, W4E82

2018. 8. 28 Korea CPHI, Attend

2018. 10. 9 Spain World CPHI, Attend

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Top acalabrutinib (ACP-196; 1420477-60-6) GMP Manufacture and acalabrutinib intermediates

GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.

Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.

www.eosmedchem.com

1.

Acalabrutinib , ACP-196, CAS# 1420477-60-6, HPLC 99.62%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock

Name: Acalabrutinib (ACP-196) 

CAS#: 1420477-60-6 

Chemical Formula: C26H23N7O2 

Exact Mass: 465.19132 

Molecular Weight: 465.52 

Elemental Analysis: C, 67.08; H, 4.98; N, 21.06; O, 6.87

Synonym: ACP-196; ACP196; ACP 196; Acalabrutinib

IUPAC/Chemical Name: (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

InChi Key: WDENQIQQYWYTPO-IBGZPJMESA-N

InChi Code: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

SMILES Code: O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2

 

2.

Acalabrutinib Intermediates:

Acalabrutinib Intermediates,  CAS# 1420478-88-1, (S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS# 1383385-64-5 , N-Pyridin-2-yl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl) -benzamide, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

, 

Acalabrutinib Intermediates,  CAS# 1420478-89-2, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#1420478-90-5, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#1418307-18-2, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#1418307-17-1, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#864759-39-7, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#850568-25-1, 4-(Pyridin-2-yl)aminocarbonylphenylboronicacid, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Acalabrutinib Intermediates,  CAS#939412-86-9, (3-Chloropyrazin-2-yl)MethanaMine hydrochloride, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

ADDITIONAL INFORMATION

Acalabrutinib is a potent and selective BTK (Bruton's tyrosine kinase) inhibitor. BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors. Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders. BTK inhibitors targeting B cell receptor signaling and other survival mechanism showed great promise for the treatment of chronic lymphocytic leukemia (CLL)s holds great promise.

As of 2015 it is in late stage clinical trials for relapsed chronic lymphocytic leukemia. Interim results are encouraging : 95% overall response rate. It is also in another 20 clinical trials (alone and in combination) for various cancers.

REFERENCES

1: Maly J, Blachly JS. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Curr Hematol Malig Rep. 2016 Feb 11. [Epub ahead of print] PubMed PMID: 26893063.

2: Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. PubMed PMID: 26641137.

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

2018. 4.18 Janpan CPHI, Attend

2018. 5.15 Israel Biomed, Attend

2018. 6. 20 China CPHI, W4E82

2018. 8. 28 Korea CPHI, Attend

2018. 10. 9 Spain World CPHI, Attend

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Biggest : Vitamin D3 derivatives, Vitamin D4 derivatives

Pls contact: info@eosmedchem.com  ,   eosmedchem@gmail.com

www.eosmedchem.com

Vitamin D4 derivatives, Paricalcitol, CAS is 131918-61-1, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D4 derivatives, 25-Hydroxyvitamin D2, CAS is 21343-40-8, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D4 derivatives, Doxercalciferol, CAS is 54573-75-0, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Alfacalcidol, CAS is 41294-56-8, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Calcifedio, CAS is 63283-36-3, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Calcitriol, CAS is 32222-06-3, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Calcipotriol hydrate, CAS is 147657-22-5, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Maxacalcitol, CAS is 103909-75-7, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, (5E,7Z)-(3R,9ξ,20S)-20-(3-Hydroxy-3-methylbuty loxy)-9,10-secopregna-1(10),5,7-triene-1,9-diol, CAS is , HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Lexacalcitol, CAS is 131875-08-6, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Eldecalcitol, CAS is 104121-92-8, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Eldecalcitol Intermediate Pro-eldecaltitol (n-4 step) , CAS is 151546-09-7, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Eldecalcitol impurity, CAS is N/A, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Trans-Eldecalcitol, CAS is N/A, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Pre-Eldecalcitol, CAS is N/A, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Tachy-Eldecalcitol, CAS is N/A, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Seocalcitol, CAS is 134404-52-7, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Secalciferol, CAS is 55721-11-4, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Elocalcitol, CAS is 199798-84-0, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Inecalcitol, CAS is 163217-09-2, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Tacalcitol monohydrate, CAS is 93129-94-3, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.
Vitamin D3 derivatives, Falecalcitriol, CAS is 83805-11-2, HPLC 98%, HNMR, C-13 NMR, MSDS, COA, MOA is ok. Stock more than 100mg. Custom synthesis could be in GMP plant.

GMP Manufacturer Semaglutide（910463-68-2) and Semaglutide Intermediates

GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.

Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.

www.eosmedchem.com

1.

Semaglutide（910463-68-2) , HPLC 99%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.

Name: Semaglutide 

CAS#: 910463-68-2 

Chemical Formula: C187H291N45O59 

Exact Mass: 4111.1154 

Molecular Weight: 4113.64 

Elemental Analysis: C, 54.60; H, 7.13; N, 15.32; O, 22.95

Synonym: Semaglutide; NNC 0113-0217

IUPAC/Chemical Name: NNC 0113-0217; L-Histidyl-2-methylalanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(17-carboxy-1-oxoheptadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine

InChi Key: NEPLHSBHWKHLHT-QLJXVRBESA-N

InChi Code: InChI=1S/C187H291N45O59/c1-18-104(10)152(178(281)208-107(13)157(260)216-132(86-113-89-200-118-50-40-39-49-116(113)118)168(271)218-128(82-101(4)5)169(272)228-150(102(6)7)176(279)215-120(53-44-74-199-185(194)195)160(263)201-91-141(243)209-119(52-43-73-198-184(192)193)159(262)204-94-149(256)257)230-170(273)130(83-110-45-33-31-34-46-110)219-165(268)125(64-69-147(252)253)214-164(267)121(51-41-42-72-197-183(287)187(291-80-79-289-76-71-189,138(240)98-290-78-77-288-75-70-188)137(239)65-60-126(181(284)285)211-140(242)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-144(246)247)212-156(259)106(12)206-155(258)105(11)207-163(266)124(61-66-139(191)241)210-142(244)92-202-161(264)122(62-67-145(248)249)213-166(269)127(81-100(2)3)217-167(270)129(85-112-56-58-115(238)59-57-112)220-173(276)134(95-233)223-175(278)136(97-235)224-177(280)151(103(8)9)229-172(275)133(88-148(254)255)221-174(277)135(96-234)225-180(283)154(109(15)237)231-171(274)131(84-111-47-35-32-36-48-111)222-179(282)153(108(14)236)227-143(245)93-203-162(265)123(63-68-146(250)251)226-182(286)186(16,17)232-158(261)117(190)87-114-90-196-99-205-114/h31-36,39-40,45-50,56-59,89-90,99-109,117,119-136,150-154,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-98,188-190H2,1-17H3,(H2,191,241)(H,196,205)(H,197,287)(H,201,263)(H,202,264)(H,203,265)(H,204,262)(H,206,258)(H,207,266)(H,208,281)(H,209,243)(H,210,244)(H,211,242)(H,212,259)(H,213,269)(H,214,267)(H,215,279)(H,216,260)(H,217,270)(H,218,271)(H,219,268)(H,220,276)(H,221,277)(H,222,282)(H,223,278)(H,224,280)(H,225,283)(H,226,286)(H,227,245)(H,228,272)(H,229,275)(H,230,273)(H,231,274)(H,232,261)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,254,255)(H,256,257)(H,284,285)(H4,192,193,198)(H4,194,195,199)/t104-,105-,106-,107-,108+,109+,117-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134+,135-,136-,150-,151-,152-,153-,154-,187?/m0/s1

SMILES Code: O=C(O)CNC([C@H](CCCNC(N)=N)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CCC(O)=O)NC([C@H](CCCCNC(C(C(COCCOCCN)=O)(C(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)OCCOCCN)=O)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC4=CC=C(O)C=C4)NC([C@@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC5=CC=CC=C5)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(C(C)(C)NC([C@H](CC6=CNC=N6)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

2

Semaglutide intermediates

Semaglutide intermediate,  CAS# 72849-35-5, Octadecanedioic acid, 1-methyl ester ,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Semaglutide intermediate,  CAS# 871-70-5, OCTADECANEDIOIC ACID ,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Semaglutide intermediate,  CAS# 189625-51-2, OCTADECANEDIOIC ACID MONOBENZYL ESTER,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Semaglutide intermediate,  CAS# 843666-40-0, Octadecanedioic acid mono-tert-butyl este,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Semaglutide intermediate,  CAS# 166108-71-0, Fmoc AEEA,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

REFERENCES

1: Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, Kiyosue A. Safety and efficacy of once-weekly semaglutide versus additional oral antidiabetic drugs, in Japanese subjects with inadequately controlled T2D: a randomised trial. Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13218. [Epub ahead of print] PubMed PMID: 29322610.

2: Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10. PubMed PMID: 29299466; PubMed Central PMCID: PMC5750268.

3: Guja C, Dănciulescu Miulescu R. Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists? Ann Transl Med. 2017 Dec;5(23):475. doi: 10.21037/atm.2017.10.09. PubMed PMID: 29285508; PubMed Central PMCID: PMC5733318.

4: Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2017 Dec 15. pii: dc170417. doi: 10.2337/dc17-0417. [Epub ahead of print] PubMed PMID: 29246950.

5: Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment. Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13186. [Epub ahead of print] PubMed PMID: 29205786.

6: Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, Helmark IC, Wijayasinghe N, Larsen M. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172. [Epub ahead of print] PubMed PMID: 29178519.

7: Hawkes N. Sixty seconds on . . . semaglutide. BMJ. 2017 Nov 1;359:j5010. doi: 10.1136/bmj.j5010. PubMed PMID: 29092887.

8: Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 Oct 17;318(15):1460-1470. doi: 10.1001/jama.2017.14752. PubMed PMID: 29049653.

9: Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13120. [Epub ahead of print] PubMed PMID: 28941314.

10: Anderson TW, Granhall C, Réthy Á, Søndergaard FL, Thomsen M. Erratum to: Abstracts of the 53rd Annual Meeting of the EASD, Lisbon 2017. Abstract 788: 'Pharmacokinetics and tolerability of oral semaglutide in subjects with renal impairment'. Diabetologia. 2017 Sep;60(Suppl 1):609. doi: 10.1007/s00125-017-4413-1. PubMed PMID: 28835978.

11: Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13082. [Epub ahead of print] PubMed PMID: 28786547.

12: Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017 Sep;26(9):1083-1089. doi: 10.1080/13543784.2017.1360274. Epub 2017 Aug 2. Review. PubMed PMID: 28741970.

13: Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399. doi: 10.1007/s00125-017-4289-0. Epub 2017 May 19. PubMed PMID: 28526920; PubMed Central PMCID: PMC5491562.

14: Sorli C. Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply. Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9. PubMed PMID: 28434491.

15: Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017 May;5(5):329-330. doi: 10.1016/S2213-8587(17)30109-2. PubMed PMID: 28434490.

16: Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. PubMed PMID: 28385659.

17: Madsbad S, Holst JJ. Glycaemic control and weight loss with semaglutide in type 2 diabetes. Lancet Diabetes Endocrinol. 2017 May;5(5):315-317. doi: 10.1016/S2213-8587(17)30094-3. Epub 2017 Apr 3. PubMed PMID: 28385658.

18: Hausner H, Derving Karsbøl J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017 Nov;56(11):1391-1401. doi: 10.1007/s40262-017-0532-6. PubMed PMID: 28349387; PubMed Central PMCID: PMC5648738.

19: Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. Clin Pharmacokinet. 2017 Nov;56(11):1381-1390. doi: 10.1007/s40262-017-0528-2. PubMed PMID: 28349386; PubMed Central PMCID: PMC5648736.

20: Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017 May;5(5):355-366. doi: 10.1016/S2213-8587(17)30085-2. Epub 2017 Mar 23. PubMed PMID: 28344112.

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

2018. 4.18 Janpan CPHI, Attend

2018. 5.15 Israel Biomed, Attend

2018. 6. 20 China CPHI, W4E82

2018. 8. 28 Korea CPHI, Attend

2018. 10. 9 Spain World CPHI, Attend

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China